Humana Inc. (HUM): Price and Financial Metrics

Humana Inc. (HUM)

Today's Latest Price: $403.91 USD

12.73 (3.25%)

Updated Aug 5 8:03pm

Add HUM to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 9 in Medical - Health Insurance

See all "A" rated Strong Buy stocks

HUM Stock Summary

  • HUM has a market capitalization of $51,716,370,071 -- more than approximately 96.09% of US stocks.
  • The capital turnover (annual revenue relative to shareholder's equity) for HUM is 5.48 -- better than 91.93% of US stocks.
  • HUM's went public 34.62 years ago, making it older than 92.88% of listed US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Humana Inc are ODP, RUSHA, SHW, FOSL, and LECO.
  • HUM's SEC filings can be seen here. And to visit Humana Inc's official web site, go to
HUM Daily Price Range
HUM 52-Week Price Range

HUM Stock Price Chart Technical Analysis Charts

HUM Price/Volume Stats

Current price $403.91 52-week high $412.70
Prev. close $391.18 52-week low $208.25
Day low $394.51 Volume 905,234
Day high $404.75 Avg. volume 1,212,040
50-day MA $390.29 Dividend yield 0.64%
200-day MA $354.59 Market Cap 53.40B

Humana Inc. (HUM) Company Bio

Humana operates as a health and well-being company. The company operates through three segments: Retail, Group, and Healthcare Services. The company was founded in 1964 and is based in Louisville, Kentucky.

HUM Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$403.91$1102.74 182%

We started the process of determining a valid price forecast for Humana Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Humana Inc ranked in the 69th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 183.17% on a DCF basis. The most interesting components of our discounted cash flow analysis for Humana Inc ended up being:

  • HUM's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 31.1% of tickers in our DCF set.
  • The weighted average cost of capital for the company is 7. This value is greater than merely 24.89% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

PCRX, DVA, NVO, TVTY, and EGRX can be thought of as valuation peers to HUM, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

HUM Latest News Stream

Event/Time News Detail
Loading, please wait...

HUM Latest Social Stream

Loading social stream, please wait...

View Full HUM Social Stream

Latest HUM News From Around the Web

Below are the latest news stories about Humana Inc that investors may wish to consider to help them evaluate HUM as an investment opportunity.

UnitedHealth Group Inc. stock falls Thursday, underperforms market

COMPANY CLOSE UPDATES Terrence Horan Shares of UnitedHealth Group Inc. UNH shed 0.47% to $305.23 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.

Yahoo | July 30, 2020

Heal Lands $100M From Humana For At-Home Care Model

The Series D round brings Heal’s total funding to $200 million and gives the company a post-money valuation of at least $300 million.

Crunchbase News | July 29, 2020

Heal raises $100 million for telehealth appointments and house calls

Heal, a health care platform that enables patients to arrange physical house calls from doctors, has raised $100 million from insurance giant Humana.

VentureBeat | July 29, 2020

Humana (HUM) Reports Next Week: Wall Street Expects Earnings Growth

Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2020

Centene CEO Says Covid-19 Vaccine Profits Should Be Capped for Companies That Took Government Aid

The CEO of (CNC) one of America’s five largest health insurers by market value, thinks that the drug companies developing Covid-19 vaccines need to keep their prices low. “My whole mentality is, when things are tough, that’s not the time to try and capitalize on it,” Centene (ticker: CNC) CEO Michael Neidorff told Barron’s on Tuesday. “I think the drug companies will have to show some restraint.”

Yahoo | July 29, 2020

Read More 'HUM' Stories Here

HUM Price Returns

1-mo 1.88%
3-mo 8.93%
6-mo 14.77%
1-year 39.23%
3-year 67.28%
5-year 126.47%
YTD 10.62%
2019 28.94%
2018 15.89%
2017 22.60%
2016 14.85%
2015 25.07%

HUM Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full HUM Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9685 seconds.